AB1193 Usage Pattern of Concomitant Therapy with Biological Dmards in Chinese Patients with Rheumatoid Arthritis: A Multi-Center Cross-Sectional Study

Abstract

BackgroundBiological disease modifying antirheumatic drugs (bDMARDs) are frequently used in combination with other drugs. Very limited data are available on concomitant therapy with bDMARDs in China.ObjectivesTo investigate the usage patterns and safety of concomitant drugs in Chinese RA patients receiving bDMARDs.MethodsPatients from 15 Chinese hospitals were recruited in this cross-sectional study. Consenting patients (aged ≥18 years) diagnosed with RA receiving bDMARDs were included.ResultsData collected from 802 patients with a mean (SD) age of 49.0 (13.9) years (81.3% women) were analyzed. Among these patients, 89.5%, 56.1%, 29.7%, and 19.1% were receiving concomitant conventional DMARDs (cDMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (GC), and drugs for local application (LA drugs), respectively. In total, 718 patients were receiving concomitant cDMARDs. The proportion of patients using 1, 2, and 3 concomitant cDMARDs was 49.3%, 41.2%, and 9.5%, respectively. The most common cDMARDs were methotrexate, hydroxychloroquine, leflunomide, and sulfasalazine; used by 65.9%, 41.8%, 41.5%, and 6.3% patients at a mean (SD) daily dose (mg) of 1.4 (0.4), 340.3 (96.3), 15.4 (5.2), and 1753.3 (693.3), respectively. The respective mean (SD) duration of treatment (days) was 443.7 (845.8), 261.3 (409.4), 413.4 (578.5), and 429.1 (1039.9). Among the 238 patients on concomitant GC, 73.1% and 23.1% patients were receiving oral prednisone and methylprednisolone at a mean (SD) weekly dose (mg) of 57.8 (31.9) and 59.7 (151.6), respectively. In total, 17.6% patients reported at least one GC-associated adverse event (AE) at a mean (SD) duration of treatment (weeks) of 12 (28.3); the most common AEs were moon face (13.9%) and weight gain (4.2%). Among the 450 patients receiving concomitant NSAIDs, 43.1%, 20.2%, and 12.0% patients were receiving celecoxib, meloxicam, and loxoprofen sodium at a mean (SD) daily dose (mg) of 306.2 (100.1), 12.8 (3.5), and 143.9 (45.3), respectively. Most NSAID users were receiving NSAIDs at a dose lower than the daily maximum, except 2 patients using diclofenac acid at higher than daily maximum dose (150 mg). Only 3.6% NSAID users reported at least one AE; the most common AE was gastrointestinal discomfort (3.1%). A total of 153 patients were receiving concomitant LA drugs. The most common LA drugs were ketoprofen, diclofenac acid, and a Chinese herb medicine “Jia Wei Shuang Bai San”, used by 30.1%, 20.9%, and 10.5% patients, respectively. The corresponding mean (SD) treatment duration (weeks) was 2.0 (4.1), 7.8 (26.4), and 16.9 (28.0), respectively. The predominant reason (62.9% patients) for not using LA drugs was the lack of physician-directed prescription.ConclusionsThe usage patterns of concomitant cDMARDs and NSAIDs in Chinese RA patients receiving bDMARDs are similar to those in Western countries. The 17.6% concomitant GC users who reported at least one AE are receiving GC for longer time (12 weeks on average). LA drugs including traditional Chinese medicine offer a broad...

Comparison of Efficacy of Acupuncture-Related Therapy in the Treatment of Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials

“…Regardless of the length of the disease, early effective treatment of RA could reduce the disability, control disease activity, and prevent and delay the patient's condition (55,56). Studies have shown that the use of non-steroidal anti-inflammatory drugs, The above data represent the confidence interval.…”

“…At present, the pathogenesis of RA is not fully understood, and it might be related to autoimmunity, infection, and heredity ( 54 ). Regardless of the length of the disease, early effective treatment of RA could reduce the disability, control disease activity, and prevent and delay the patient’s condition ( 55 , 56 ). Studies have shown that the use of non-steroidal anti-inflammatory drugs, DMARDs, and steroid would cause serious side effects, and drug resistance in some patients, which may seriously reduce the therapeutic effect ( 57 ).…”

The efficacy and safety of silver needle in the treatment of rheumatoid arthritis

“…At present, the pathogenesis of rheumatoid arthritis is not fully understood, which may be related to autoimmune factors, infection and heredity [20] . No matter the duration of the disease, early and effective treatment of RA patients can reduce their disability rate, control the disease activity of patients, help to prevent and delay the disease of patients, and is also the key to the treatment of rheumatoid arthritis [21,22] . Clinical observation found that non-steroidal anti-inflammatory drugs, anti-rheumatic drugs and steroid drugs and other drugs in the use process, in addition to toxic side effects, but also showed a gradual failure trend, and some patients will develop drug resistance, seriously reducing the therapeutic effect [23] .…”